New Two-Pronged attack tested for Tough-to-Treat cancers

This trial is testing whether a combination of two targeted drugs, trastuzumab and pertuzumab, can help control advanced cancers that have a specific genetic feature called HER2 amplification. The study is for patients whose cancers are not breast, stomach, or colorectal, as these drugs are already approved for those types. The goal is to see if this drug combo can shrink tumors or stop them from growing in people who have few other treatment options.